EKG Recommendation for Patients on Seroquel (Quetiapine)
Yes, an electrocardiogram (EKG/ECG) should be obtained before starting quetiapine (Seroquel) as part of baseline monitoring for all patients. 1
Baseline Monitoring Requirements
The most recent international schizophrenia treatment guidelines explicitly recommend obtaining an electrocardiogram before starting antipsychotic treatment, including quetiapine 1. This is part of comprehensive baseline assessment that should include:
- ECG (mandatory)
- BMI and waist circumference
- Blood pressure
- HbA1c and glucose
- Lipid panel
- Prolactin, liver function tests
- Urea, electrolytes, and full blood count
Risk Stratification for Follow-Up ECG Monitoring
While baseline ECG is recommended for all patients, the need for repeat ECG monitoring depends on individual risk factors 2:
High-Risk Patients Requiring Serial ECG Monitoring:
- Elderly patients (particularly women)
- Baseline QTc > 450 ms (men) or > 470 ms (women)
- Concurrent QT-prolonging medications (antidepressants, antibiotics, antiarrhythmics)
- Electrolyte disturbances (hypokalemia, hypomagnesemia)
- Heart failure or structural heart disease
- Renal impairment (quetiapine accumulation risk)
- Patients on diuretics
When to Repeat ECG:
- After dose escalation in high-risk patients
- When adding other QT-prolonging medications
- If cardiac symptoms develop (palpitations, syncope, dizziness)
- At 3 months after initiation, then annually 1
Clinical Context and Evidence
Quetiapine is classified as an antipsychotic with QT-prolonging potential 2. Recent high-quality research demonstrates that more than 10% of patients receiving quetiapine develop severe QT prolongation (QTc > 500 ms or increase > 60 ms) 3. Critically, this severe QT prolongation was significantly associated with:
- Ventricular arrhythmias (odds ratio 2.84)
- Sudden cardiac death (odds ratio 2.29) 3
The 2023 Canadian Cardiovascular Society guidelines clarify that routine ECG is not required for every patient starting low-risk QT-prolonging drugs in low-risk settings 2. However, quetiapine falls into an intermediate-risk category where clinical judgment is essential. The guidelines specifically state: "Consider an ECG before initiation of a QT-prolonging drug if an electrolyte disturbance is present, if already receiving a QT-prolonging drug, or when initiating a high-risk QT-prolonging drug" 2.
Common Pitfalls to Avoid
Don't skip baseline ECG: Even though older literature suggested ECG wasn't mandatory 4, current best-practice guidelines from 2025 explicitly recommend it 1
Don't ignore risk factors: The mean QTc increase with quetiapine is modest (+8.3 ms) 3, but individual responses vary dramatically based on risk factors
Monitor electrolytes: Hypokalemia and hypomagnesemia are modifiable risk factors that significantly increase arrhythmia risk 2
Check drug interactions: Use resources like www.crediblemeds.org to identify concurrent QT-prolonging medications 2
Be especially vigilant in elderly women: This demographic has the highest risk for drug-induced QT prolongation 2
Practical Algorithm
Step 1: Obtain baseline ECG for all patients before starting quetiapine 1
Step 2: Assess risk factors (age, sex, cardiac history, concurrent medications, electrolytes)
Step 3:
- Low risk (young, healthy, no risk factors): Repeat ECG at 3 months, then annually 1
- High risk (≥2 risk factors present): Repeat ECG after reaching therapeutic dose and with any dose changes
Step 4: If QTc > 500 ms or increase > 60 ms develops, consider dose reduction, switching to alternative antipsychotic, or cardiology consultation 2
The evidence strongly supports baseline ECG as standard practice, with individualized follow-up monitoring based on risk stratification rather than routine serial ECGs for all patients.